-
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-27 Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer, Justin M. Watts
Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and...
-
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-27 Andrew Matthews, Elena Fenu, Sarah J. Skuli, Jaryse C. Harris, Catherine Lai
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-22 Maria-Myrsini Tzioni, Alexandra Clipson, Zi Chen, Francesco Cucco, Andrew Wotherspoon, Stefan Dojcinov, Ming-Qing Du
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Significant impact of antibiotic exposure on GI-GVHD, NRM, and GRFS following allogeneic HCT with non-myeloablative Flu-TBI conditioning Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-23 Lenneke F. J. van Groningen, Suzanne van Dorp, Manita E. J. Bremmers, Shahira Fazel, Mieke W. H. Roeven, Nicole M. A. Blijlevens, Walter J. F. M. van der Velden
Acute gastro-intestinal graft-versus-host disease (GI-GVHD) and non-relapse mortality (NRM) after allogeneic HCT are closely related to loss of microbial diversity and intestinal dominance by singl...
-
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-22 Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K. Barta, Seda Tolu, Brian Estrella, Ahmed Sawas, Jennifer K. Lue, Mark M. Francescone, Barbara Pro, Jennifer E. Amengual
Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II stu...
-
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-21 Aya M. Abdallah, Hanafy Hafez, Youssef Madney, Sonia Ahmed, Dina Yassin, Sherine Salem, Rodina Yousry, Hisham Abdel-Azim, Leslie Lehmann, Alaa Elhaddad
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-20 Lin-Rui Gao, Xinyue Wang, Yunpeng Wu, Xiao-Li Feng, Wei Rao, Xin Liu, Yong-Wen Song, Hui Fang, Bo Chen, Jing Jin, Yue-Ping Liu, Hao Jing, Yuan Tang, Ning-Ning Lu, Ning Li, Wen-Wen Zhang, Yirui Zhai, Shu-Lian Wang, Shu-Nan Qi, Ye-Xiong Li
The disease failure patterns and optimal treatment of bronchus-associated lymphoid tissue (BALT) lymphoma are unknown. This retrospective study involved 71 patients with primary BALT lymphoma who h...
-
RAD21 mutations in acute myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-20 Dorottya Laczko, Corey Poveda-Rogers, Andrew H. Matthews, Oraine Snaith, Selina Luger, Adam Bagg, Gabriel C. Caponetti, Jennifer J.D Morrissette, Guang Yang
The cohesin complex is a ring-shaped protein structure involved in DNA repair and chromosomal segregation. Studies have showed that genomic alterations in the cohesin complex members are among the ...
-
Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-19 Gilad Itchaki, Osnat Jarhovsky, Jorge J. Castillo, Hamza Hassan, Moshe L. Gatt, Merav Leiba, Pia Raanani, Morie A. Gertz, Iuliana Vaxman
The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a sm...
-
Corynebacterium bacteremia in patients with hematologic disorders: a case series and systematic literature review Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Tomohito Shimada, Kazuhiro Ishikawa, Fujimi Kawai, Nobuyoshi Mori
Corynebacterium is generally considered a contaminant in clinical practice. However, it may cause bacteremia in patients with hematologic disorders, and factors that contribute to its mortality are...
-
Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells via modulation of NF-κB, AP-1, and Akt signaling Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-15 Chie Ishikawa, Naoki Mori
Adult T-cell leukemia (ATL), caused by HTLV-1, is the most lethal hematological malignancy. NEDD8-activating enzyme (NAE) is a component of the NEDD8 conjunction pathway that regulates cullin-RING ...
-
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-19 Vikas Gupta, Stephen Oh, Timothy Devos, Viviane Dubruille, John Catalano, Tim C. P. Somervaille, Uwe Platzbecker, Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, Jiri Mayer, Arpad Illes, Catherine Ellis, Zhaohui Wang, Francisco J. Gonzalez Carreras, Bryan Strouse, Ruben Mesa
A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 ...
-
Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Li Li, Wenjing Yang, Yuanyuan Pan, Ruyu Ye, Yu Wang, Sijia Li, Haoyan Jiang, Qi Zhang, Xiaobo Wang, Jinsong Yan
Chidamide (CS055/HBI-8000, tucidinostat) has shown promising effects in the clinical treatment of various hematologic tumors. Diffuse large B-cell lymphoma (DLBCL) has shown highly heterogeneous bi...
-
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios Athanasios Dimopoulos
Once-weekly carfilzomib at 56 mg/m2 plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT ...
-
Pairing obinutuzumab with venetoclax in relapsed CLL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Kerry A. Rogers, Philip A. Thompson
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-14 Thulasi Raman Ramalingam
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-12 Jinjin Zhu, Mimi Xu, Yuhua Ru, Huanle Gong, Yiyang Ding, Ziling Zhu, Yang Xu, Yi Fan, Xiang Zhang, Yuqing Tu, Aining Sun, Huiying Qiu, Zhengming Jin, Xiaowen Tang, Yue Han, Chengcheng Fu, Suning Chen, Xiao Ma, Feng Chen, Tiemei Song, Depei Wu, Jia Chen
Cytomegalovirus (CMV) reactivation increases treatment-related mortality (TRM) after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed 141 adult acute leukemia (AL) patients suf...
-
The value of bispecific antibodies in relapsed and refractory DLBCL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-07 Katharine Louise Lewis, Chan Yoon Cheah
Diffuse large B-cell lymphoma (DLBCL) may be cured with anti-CD20 based chemoimmunotherapy in the majority of cases, however, relapsed/refractory disease occurs in 30–40% patients, and despite sign...
-
Correction Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-09
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-09 Max J. Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon, Milos D. Miljkovic, Thomas Waldmann, Mark Roschewski
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-08 Brian T. Hill, Yanwen Chen, Deepa Jagadeesh, Robert Dean, Omer Koc, Kirsten Boughan, Brenda Cooper, Brad Pohlman, Paolo Caimi, Mitchell R. Smith
Lenalidomide and rituximab (R2) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteas...
-
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-05 Marie Leroy, Laure Deramoudt, Marine Pinturaud, Julie Demaret, Enagnon Kazali Alidjinou, Morgane Nudel, Doriane Cavalieri, Wadih Abou Chahla, Pascal Odou, Franck Morschhauser, Ibrahim Yakoub-Agha, Nicolas Simon, David Beauvais
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-07 Wisdom Akingbemi, Goldie Kurtz, Nikhil Yegya-Raman, John P. Plastaras, Stephen J. Schuster, Elise A. Chong
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-03 Jacob Fang, Grace Bosma, Dara Aisner, Christine McMahon, Maria Amaya, Marc Schwartz, Jeff Kaiser, Diana Abbott, Zenggang Pan, Jeffrey Schowinsky, Changlee Pang, Jonathan A. Gutman, Daniel A. Pollyea
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts in marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. ...
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-05 Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T. Nawas, Michael W. Drazer, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Anand A. Patel
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-03 C. Quivoron, J.-M. Michot, A. Danu, H. Lecourt, V. Saada, K. Saleh, V. Vergé, S. Cotteret, O. A. Bernard, V. Ribrag
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular res...
-
A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-28 Stavroula Asimakopoulou, Panagiotis Malandrakis, Aikaterini Kamiliou, Maria Gavriatopoulou, Konstantina Bafa, Vaios Samaras, Amalia Anastasopoulou, Eleni Variami, Eleftheria Lakiotaki, Penelope Korkolopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Cholongitas
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-29 Adrian Minson, Michael Dickinson
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes – an unusual clinicopathologic presentation with hyperdiploid clone Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-26 Sudipta Naskar, Tanusree Paul, Jayashree D. Kulkarni, K. C. Anand, V. Divya, Harshitha D. Rambhojun
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Mehrnoosh Tashakori, L. Jeffrey Medeiros
Transformation of follicular lymphoma (FL) to a Langerhans cell (LC) neoplasm is extremely uncommon. The shared IGH::BCL2 rearrangement is a robust finding in most transformed tumors underscoring t...
-
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S. Abramson, Robert Redd, Hannah K. Gilman, Terry Ho, Jessica Wu, Julius Heemelaar, Donna Neuberg, Ephraim P. Hochberg, Jeffrey A. Barnes, Philippe Armand, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Robb S. Friedman, Ann S. LaCasce, Tomas G. Neilan, Jacob D. Soumerai
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We p...
-
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-23 Naveen Pemmaraju, Yazan F. Madanat, David Rizzieri, Salman Fazal, Raajit Rampal, Gabriel Mannis, Eunice S. Wang, James Foran, Andrew A. Lane
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all pa...
-
Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-22 Chong Wei, Feifei Zhai, Congwei Jia, Wei Zhang, Daobin Zhou, Yan Zhang
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-22 Kevin D. Hofer, Marco M. Bühler, Marco Roncador, Markus Rechsteiner, Ewerton M. Maggio, Joëlle Tchinda, Urs Schanz, Eugenia Haralambieva, Corinne C. Widmer
There is increasing evidence that therapy-related acute lymphoblastic leukemia (trALL) resulting from chemo- and/or radiotherapy represents a distinct entity. However, apart from KMT2A rearrangemen...
-
Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Felix Barajas Ordonez, Denise Wolleschak, Yannic Zeller, Mattes Hinnerichs, Pablo Rodríguez-Feria, Anar Aghayev, Martin Mikusko, Jan Borggrefe, Dimitrios Mougiakakos, Alexey Surov
Studies regarding the influence of body composition parameters as predictors on overall survival (OS) in patients with multiple myeloma (MM) are scarce. OS and progression-free survival (PFS) were ...
-
A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-19 Lindsey Murphy, Bradford Siegele, Billie Carstens, Lisa Hartman, Kelly Faulk
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021 Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-13 Anju Murayama, Hinari Kugo, Sae Kamamoto
Financial interactions between healthcare industry and pediatric hematologist/oncologists (PHOs) could be conflicts of interest. Nevertheless, little is known about financial relationships between ...
-
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-12 Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), where effective treatments options are limited, B-cell maturation antigen and CD3-directed bispecific antibodies offer ...
-
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-10 Simon Østergaard, Lone Schejbel, Marie Fredslund Breinholt, Mette Ølgod Pedersen, Troels Hammer, Lars Munksgaard, Peter Nørgaard, Estrid Høgdall, Lise Mette Rahbek Gjerdrum, Torsten Holm Nielsen
Next-generation sequencing (NGS) affords comprehensive insights into the genomic landscape of lymphomas. We examined the mutational pattern in patients with Waldenström macroglobulinemia (WM) or ly...
-
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-12 Katja Weisel, Meletios A. Dimopoulos, Meral Beksac, Xavier Leleu, Joshua Richter, Bart Heeg, Sachin Patel, Istvan Majer, Ian McFadden, Joseph Mikhael
Nearly all patients with multiple myeloma eventually relapse or become refractory to treatment. Lenalidomide is increasingly administered in the frontline until disease progression or intolerance t...
-
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-09 Kenny Tang, Jeffrey H. Lipton
Due to the remarkable success of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML), allogeneic stem cell transplantation (alloSCT) is not first-line treatment for delivering durabl...
-
NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-09 Ehsan Tabari, Alexander F. Lovejoy, Hai Lin, Christopher R. Bolen, Seng Lor Saelee, Joshua P. Lefkowitz, David M. Kurtz, Alessia Bottos, Tina G. Nielsen, Joana M. Parreira, Khai T. Luong
Personalized risk stratification and treatment may help improve outcomes among patients with diffuse large B-cell lymphoma (DLBCL). We developed a next-generation sequencing (NGS)-based method to a...
-
The psychological needs of adolescents and young adults with a diagnosis of myeloproliferative neoplasms: a systematic scoping review of the literature Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-07 Tara Houlihan, Dónal G. Fortune, Clodagh Keohane, Helen L. Richards
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-07 Jean A. Yared, Tsung-Ying Lee, Catherine E. Cooke, Abree Johnson, Amanda Summers, Keri Yang, Sizhu Liu, Boxiong Tang, Eberechukwu Onukwugha
This study characterizes the patterns and timing of CLL treatment and, to our knowledge, is the first to identify social vulnerability factors associated with CLL treatment receipt in the Medicare ...
-
Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-05 Cynthia M. Magro, Taylor Kalomeris, Christina R. Shreve, Julia T. Geyer, Sanjay S. Patel
T cell dyscrasias that demonstrate a proclivity for the subcutaneous fat include atypical lymphocytic lobular panniculitis, lupus profundus, and primary subcutaneous T cell lymphoma, including subc...
-
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-08 Sylvain Garciaz, Guillaume Berton, Marie-Anne Hospital, Arnaud Guille, José Adélaïde, Colombe Saillard, Yosr Hicheri, Marie-Joëlle Mozziconacci, Estelle Duprez, Christian Récher, Anne-Sophie Alary, Daniel Birnbaum, Norbert Vey
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Hematopoietic cell transplantation (HCT) in MDS patients of older age Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-05 Christian Niederwieser, Nicolaus Kröger
Hematopoietic cell transplantation (HCT) has evolved to an essential treatment in younger and more recently in elderly patients with myelodysplastic syndrome (MDS), the age group with the highest i...
-
Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-01 Seiichi Okabe, Mitsuru Moriyama, Akihiko Gotoh
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-31 Amen Allah Nasr, Xavier Fund, Sylvain Barreau, Christophe Desterke, Claire Borie, Noufissa Oudrhiri, Jamila Faivre, A. Bennaceur-Griscelli, A. G. Turhan
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-31 Matthew M. Lei, Mark N. Sorial, Uvette Lou, Michelle Yu, Andrea Medrano, Josie Ford, Ronald A. Nemec, Jeremy S. Abramson, Jacob D. Soumerai
Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-w...
-
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Sumedha Arya, Lee Mozessohn, Inna Gong, Neil Faught, Ning Liu, Simron Singh, Kelvin Chan, Matthew C. Cheung
The aim of this study was to describe the impact of marginalization on DLBCL overall survival (OS) within the Canadian setting. We conducted a population-based retrospective cohort study of adult p...
-
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-22 Anath C. Lionel, Ashwath Gurumurthi, Ahmed Fetooh, Rami Eldaya, Sairah Ahmed, Swaminathan P. Iyer, Loretta J. Nastoupil, Jason Westin, Ranjit Nair, Luis Fayad, Luis Malpica, Sudhakar Tummala, Christopher Flowers, Sattva S. Neelapu, Michael L. Wang, Preetesh Jain
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-22 Ivan Krecak, Danijela Lekovic, Dragana Grohovac, Anica Sabljic, Hrvoje Holik, Ivan Zekanovic, Martina Moric Peric, Davor Galusic, Vlatka Perisa, Filip Krecak, Marko Skelin, Marko Lucijanic
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-22 Tamar Tadmor, Ilana Levy Yurkovski
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Serena Tharakan, John Mascarenhas, Douglas Tremblay
Myeloproliferative neoplasms (MPNs) that lack the classical “driver mutations,” termed triple negative MPNs, remain a poorly understood entity. Despite considerable progress toward understanding MP...
-
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Craig W. Freyer, Alison Carulli, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Mary Ellen Martin, Selina M. Luger, David L. Porter, Edward A. Stadtmauer, Alison W. Loren
Calcineurin inhibitor pain syndrome (CIPS) is a rare complication of graft-vs-host disease prophylaxis following allogeneic hematopoietic cell transplant (alloHCT). CIPS presents as severe bilatera...
-
Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Clare Grieve, Ashlee Joseph, Pamela Drullinsky, Andrew D. Zelenetz, Paul Hamlin, Anita Kumar
This dose-finding study evaluated safety of venetoclax plus Bendamustine-Rituximab-Ibrutinib in relapsed/refractory MCL. Six 28-day cycles were administered in a 3 + 3 dose-escalation design. Dose ...
-
BCMA CAR-T cells in multiple myeloma–ready for take-off? Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Lukas Scheller, Erius Tebuka, Peter Fabian Rambau, Hermann Einsele, Michael Hudecek, Sabrina Rebecca Prommersberger, Sophia Danhof
Although the approval of new drugs has improved the clinical outcome of multiple myeloma (MM), it was widely regarded as incurable over the past decades. However, recent advancements in groundbreak...
-
Comparison of two reduced intensity conditioning regimens: Flu-Bu2 versus RIC-TBF in allogeneic hematopoietic stem cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Emma Verstraete, Cédric Baumann, Hélène Rousseau, Arnaud Campidelli, Marie-Thérèse Rubio, Maud D’Aveni
Published in Leukemia & Lymphoma (Vol. 65, No. 2, 2024)
-
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Shaimaa El-Ashwah, Jon Salmanton-García, Yavuz M. Bilgin, Federico Itri, Pavel Žák, Barbora Weinbergerová, Luisa Verga, Ali S. Omrani, Maria Gomes da Silva, Tomáš Szotkowski, Monia Marchetti, Caterina Buquicchio, Marcio Nucci, Martin Schönlein, Francesca Farina, Caroline Besson, Lucia Prezioso, Summiya Nizamuddin, Julio Dávila-Valls, Sonia Martín-Pérez, Valentina Bonuomo, Jaap Van Doesum, Maria Chiara
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from...